MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Boston Scientific Corp.

Geschlossen

BrancheGesundheitswesen

98.71 -1.35

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

97.25

Max

100

Schlüsselkennzahlen

By Trading Economics

Einkommen

-138M

562M

Verkäufe

352M

4.6B

KGV

Branchendurchschnitt

80.704

63.778

EPS

0.7

Gewinnspanne

12.322

Angestellte

53,000

EBITDA

-41M

1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+20.26% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.9B

149B

Vorheriger Eröffnungskurs

100.06

Vorheriger Schlusskurs

98.71

Nachrichtenstimmung

By Acuity

47%

53%

156 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Boston Scientific Corp. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. März 2025, 12:35 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5. Feb. 2025, 12:23 UTC

Ergebnisse

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8. Jan. 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4. Nov. 2024, 13:01 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Medical-Technology Company Cortex

3. März 2025, 11:59 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3. März 2025, 11:58 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3. März 2025, 11:58 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5. Feb. 2025, 21:33 UTC

Ergebnisse

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. Feb. 2025, 15:20 UTC

Ergebnisse

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. Feb. 2025, 11:39 UTC

Ergebnisse

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5. Feb. 2025, 11:39 UTC

Ergebnisse

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5. Feb. 2025, 11:38 UTC

Ergebnisse

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5. Feb. 2025, 11:38 UTC

Ergebnisse

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Adj EPS 70c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Sales $4.56B >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q EPS 38c >BSX

8. Jan. 2025, 12:10 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8. Jan. 2025, 12:09 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8. Jan. 2025, 12:09 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8. Jan. 2025, 12:08 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8. Jan. 2025, 12:07 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8. Jan. 2025, 12:07 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8. Jan. 2025, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25. Nov. 2024, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15. Nov. 2024, 13:43 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Peer-Vergleich

Kursveränderung

Boston Scientific Corp. Prognose

Kursziel

By TipRanks

20.26% Vorteil

12-Monats-Prognose

Durchschnitt 120.32 USD  20.26%

Hoch 135 USD

Tief 108 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Boston Scientific Corp. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

23 ratings

22

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

99.3 / 101.49Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

156 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.